Clinical trial
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal…
NCT02735239 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT02735239 |
|---|---|
| Title | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer |
| Official title | Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Durvalumab, Tremelimumab, Oxaliplatin, Capecitabine, Radiotherapy, Paclitaxel, Carboplatin, 5-fluorouracil (5-FU), Leucovorin, Docetaxel |
| Enrollment | 73 |
| Start date | Jun 24, 2016 |
| Primary completion | Jun 16, 2022 |
| Completion | Jun 16, 2022 |
| First posted | Apr 12, 2016 |
| Last update posted | Mar 22, 2024 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: